Applied Therapeutics (Applied Therapeutics) Earnings Yield (Joel Greenblatt) % : -27.47% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics Earnings Yield (Joel Greenblatt) %?

Applied Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $235.19 Mil. Applied Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-64.54 Mil. Applied Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -27.47%.

The historical rank and industry rank for Applied Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

APLT' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -293.77 Med: -40.69 Max: -8.81
Current: -14.86

During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Applied Therapeutics was -8.81%. The lowest was -293.77%. And the median was -40.69%.

APLT's Earnings Yield (Joel Greenblatt) % is ranked better than
50.68% of 1395 companies
in the Biotechnology industry
Industry Median: -15.58 vs APLT: -14.86

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Applied Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

Applied Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Applied Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Therapeutics Earnings Yield (Joel Greenblatt) % Chart

Applied Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings Yield (Joel Greenblatt) %

Get a 7-Day Free Trial

-9.73

-23.53

-67.57

-1,111.11

-27.47

Applied Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings Yield (Joel Greenblatt) %	Get a 7-Day Free Trial															-1,111.11	-400.00	-144.93	-40.16	-27.47

Competitive Comparison of Applied Therapeutics's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Applied Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Applied Therapeutics's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Applied Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.

Applied Therapeutics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Applied Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)	=	EBIT	/	Enterprise Value
	=	-64.535	/	235.19283
	=	-27.44 %

Applied Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.54 Mil.

Applied Therapeutics (NAS:APLT) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.

Be Aware

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.

Applied Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Therapeutics (Applied Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » Earnings Yield (Joel Greenblatt) %

Comparable Companies

Traded in Other Exchanges

2UV:Germany

Address

545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017

Website

https://www.appliedtherapeutics.com

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need.

Executives

Stacy J. Kanter	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Shoshana Shendelman	director, 10 percent owner, officer: President and CEO	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Adam Hansard	officer: Chief Commercial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017
Riccardo Perfetti	officer: Chief Medical Officer	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Alexandria Real Estate Equities, Inc.	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Catherine Thorpe	officer: Chief Accounting Officer	545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Chids Mahadevan	officer: Chief Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Steven A. Ortega	officer: Principal Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Charles Silberstein	officer: Chief Financial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Alexandria Equities No. 7, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jay S Skyler	director	DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
Alexandria Venture Investments, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Teena Lerner	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173